Treatment of advanced pancreatic cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Labianca, R ^a   Merelli, B ^a   Mosconi, S ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Advanced; Cancer; Chemotherapy; Innovative treatments; Pancreas

Indexed keywords

CISPLATIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LIFE EXPECTANCY; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PLATINUM;

EID: 84866766583     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds355     Document Type: Article

References (10)

1. Huguet F, Girard N, Guerche CS et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 227: 2269-2277.
2. Huguet F, Andrè T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
3. Colucci G, Labianca R, Di Costanzo F et al. Randomized phase iii trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28: 1645-1651.
4. Sultana A, Smith CT, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615.
5. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
6. Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29: 4548-4554.
7. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
8. Mancuso A, Sacchetta S, Saletti PC et al. Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer Res 2010; 30: 4289-4295.
9. Zaniboni A, Aitini E, Barni S et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012; 69: 1641-1645.
10. Van Laethem JL, Verslype C, Iovanna JL et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 2012; 23: 570-576.